Study S001928

A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT01625260
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1; PHASE2
Masking: NONE
Status: TERMINATED
Enrollment: 12
Start: 2012-03-30
Primary completion: 2018-03-08
Lead sponsor: Altor BioScience
Conditions: Non-muscle Invasive Bladder Cancer
Interventions: BIOLOGICAL:ALT-801; DRUG:Gemcitabine
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Safety Profile [12 weeks]
Disease Response Rate [From start of study treatment to up to 13 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.